Respiratory Inhalers Honeywell Inaugurates New Plant for GWP Medical Propellant

Related Vendors

Honeywell International Inc. World Headquarters

TURCK GmbH

Glatt Ingenieurtechnik GmbH

ProMinent GmbH

Honeywell’s new plant in Baton Rouge, Louisiana, USA will produce Solstice Air, a near-zero global-warming-potential (GWP) medical propellant which will be used by Astra Zeneca for manufacturing next-generation respiratory inhalers.

New Jersey/USA – Honeywell recently announced the opening of a plant in Baton Rouge, La., that is the company's first large-scale manufacturing site for Solstice Air, a near-zero global-warming-potential (GWP) medical propellant for use in respiratory inhalers. Solstice Air is a non-flammable, near-zero GWP, non-ozone-depleting, volatile organic compound (VOC)-exempt (per U.S. EPA and Carb) propellant in clinical development today for pressurized metered-dose inhalers (Pmdis).

Astra Zeneca is working to incorporate Honeywell's Solstice Air technology, which is being evaluated for use as a medical propellant and has up to 99.9 % less GWP than propellants currently used in inhaled respiratory medicines. Astra Zeneca expects their triple-combination therapy Breztri Aerosphere (budesonide/ glycopyrronium/ formoterol fumarate) to be the first medicine to transition to the next-generation propellant, subject to regulatory approval, followed by the rest of their Pmdi portfolio.

"Astra Zeneca's commercial partnership with Honeywell is an excellent example of a true commitment to advancing healthcare innovation to improve outcomes both for patients and the planet," said Pablo Panella, senior vice president, Global Respiratory & Immunology, Astra Zeneca. "Through close collaboration and extensive knowledge sharing between our two companies, we are committed to bringing the next generation of inhaled medicines with near-zero GWP propellant to patients. Honeywell's ability to escalate the production of Solstice Air at their new manufacturing site will help enable us to move quickly on this ambition once regulatory approval is achieved."

Ken West, president of Honeywell Advanced Materials said, "The opening of this plant in Baton Rouge is Honeywell's first site to produce medical grade propellant and our continued work with Astra Zeneca offers a critical moment to highlight how Honeywell's Solstice technology plays an important role in helping the pharmaceutical industry meet its sustainability goals while supporting essential care for respiratory patients worldwide."

Honeywell has invested more than one billion dollars in research, development and new capacity for its Solstice technology, having anticipated the need for lower-GWP solutions to combat climate change more than a decade ago. The Solstice product line, which helps customers lower their greenhouse gas emissions and improve energy efficiency without sacrificing end-product performance, includes refrigerants for supermarkets, air conditioning for cars and trucks, blowing agents for insulation, propellants for personal and household care and solvents for cleaning solutions.

Using Honeywell Solstice technology has helped avoid the potential release of the equivalent of more than 295 million metric tons of carbon dioxide into the atmosphere so far, equal to the carbon emissions from nearly 688 million barrels of oil.

(ID:48647615)